Lenvatinib, quavonlimab, TRETINOIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, vibostolimab clinical trials

A Phase 1/2 Open-label, Rolling-arm, Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYMAKER-U02): Substudy 02A

This study is testing new combinations of medicines for advanced melanoma that hasn't responded to previous treatment. Researchers want to see if these new treatments are safe and if they can shrink tumours. It's for adults aged 18 and over.